Apitope appoints Dr Geoffrey Vernon chairman
This article was originally published in Scrip
Executive Summary
Apitope International (Belgium), a developer of peptide-based therapies for autoimmune diseases and allergy, has named Dr Geoffrey Vernon chairman. He succeeds Richard Daniels, who continues as a non-executive director. Dr Vernon has more than 30 years' experience in healthcare through the UK's national health service and companies including Ciba-Geigy Pharmaceuticals, Schering Chemicals and Travenol Laboratories.